Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 8, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Ulcerative Colitis (UC)Crohn Disease (CD)
Interventions
DRUG

Risankizumab-800CW 4.5 mg

Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.

DRUG

Risankizumab-800CW 15 mg

Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.

DRUG

Risankizumab-800CW 25 mg

Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.

DRUG

Risankizumab-800CW optimal dose

Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.

Trial Locations (1)

9713GZ

RECRUITING

University Medical Center Groningen, Groningen

All Listed Sponsors
lead

University Medical Center Groningen

OTHER